Galmed Pharmaceuticals Ltd. (GLMD)Healthcare | Biotechnology | Ramat Gan, Israel | NasdaqCM
0.76 USD
+0.02
(2.233%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 0.73 -0.03 (-0.026%) ⇩ (April 17, 2026, 7:58 p.m. EDT) Short-term: ☆☆☆☆☆ | Long-term: ★★☆☆☆ | Dividends: ★☆☆☆☆ |
Hot Take | April 18, 2026, 11:24 p.m. EDT
Despite favorable recent headlines regarding the Aramchol technology and a noticeable price rebound, the forecasting model signals a strong short-term downside (approx -5.4% predicted move), driven by negative earnings momentum (negative EPS and cash flow), making this a clear short signal despite the long-term turnaround potential. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.089174 |
| AutoARIMA | 0.120118 |
| AutoETS | 0.250309 |
| MSTL | 0.271582 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 28% |
| H-stat | 2.65 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 3.67 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 4,986,038 |
| Forward P/E | -0.73 |
| Beta | 0.47 |
| Website | https://galmedpharma.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.45999998 |
| Address1 | 16 Abba Hillel Road |
| All Time High | 4,870.8 |
| All Time Low | 0.411 |
| Ask | 0.7739 |
| Ask Size | 1 |
| Average Analyst Rating | 3.0 - Hold |
| Average Daily Volume10 Day | 18,500,020 |
| Average Daily Volume3 Month | 3,073,924 |
| Average Volume | 3,073,924 |
| Average Volume10Days | 18,500,020 |
| Beta | 0.47 |
| Bid | 0.7014 |
| Bid Size | 1 |
| Book Value | 2.398 |
| City | Ramat Gan |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Israel |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.7555 |
| Current Ratio | 6.547 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 0.76 |
| Day Low | 0.7126 |
| Display Name | Galmed Pharmaceuticals |
| Earnings Timestamp End | 1,756,756,800 |
| Earnings Timestamp Start | 1,756,238,400 |
| Ebitda | -8,427,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 1.564 |
| Enterprise Value | -13,183,760 |
| Eps Forward | -1.03 |
| Eps Trailing Twelve Months | -2.39 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 972 3 693 8447 |
| Fifty Day Average | 0.618 |
| Fifty Day Average Change | 0.13750005 |
| Fifty Day Average Change Percent | 0.222492 |
| Fifty Two Week Change Percent | -45.999996 |
| Fifty Two Week High | 2.68 |
| Fifty Two Week High Change | -1.9245 |
| Fifty Two Week High Change Percent | -0.718097 |
| Fifty Two Week Low | 0.411 |
| Fifty Two Week Low Change | 0.3445 |
| Fifty Two Week Low Change Percent | 0.8381995 |
| Fifty Two Week Range | 0.411 - 2.68 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,394,717,400,000 |
| Float Shares | 6,368,087 |
| Forward Eps | -1.03 |
| Forward P E | -0.7334952 |
| Free Cashflow | -3,828,125 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 3 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00991 |
| Held Percent Institutions | 0.03385 |
| Implied Shares Outstanding | 6,599,654 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,724,976,000 |
| Last Split Factor | 1:12 |
| Long Business Summary | Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel. |
| Long Name | Galmed Pharmaceuticals Ltd. |
| Market | us_market |
| Market Cap | 4,986,038 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_114779940 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -10,309,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 4,896,943 |
| Open | 0.7168 |
| Operating Cashflow | -6,315,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 972 3 693 8448 |
| Post Market Change | -0.025700033 |
| Post Market Change Percent | -3.401725 |
| Post Market Price | 0.7298 |
| Post Market Time | 1,776,470,314 |
| Previous Close | 0.739 |
| Price Hint | 4 |
| Price To Book | 0.3150542 |
| Profit Margins | 0.0 |
| Quick Ratio | 6.41 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | hold |
| Recommendation Mean | 3.0 |
| Region | US |
| Regular Market Change | 0.0165 |
| Regular Market Change Percent | 2.23275 |
| Regular Market Day High | 0.76 |
| Regular Market Day Low | 0.7126 |
| Regular Market Day Range | 0.7126 - 0.76 |
| Regular Market Open | 0.7168 |
| Regular Market Previous Close | 0.739 |
| Regular Market Price | 0.7555 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 281,116 |
| Return On Assets | -0.28652 |
| Return On Equity | -0.64212996 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 6,599,654 |
| Shares Percent Shares Out | 0.0028 |
| Shares Short | 18,755 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 26,832 |
| Short Name | Galmed Pharmaceuticals Ltd. |
| Short Percent Of Float | 0.0029 |
| Short Ratio | 0.87 |
| Source Interval | 15 |
| Symbol | GLMD |
| Total Cash | 18,156,000 |
| Total Cash Per Share | 2.759 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.39 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.124155 |
| Two Hundred Day Average Change | -0.36865503 |
| Two Hundred Day Average Change Percent | -0.32793966 |
| Type Disp | Equity |
| Volume | 281,116 |
| Website | https://galmedpharma.com |
| Zip | 5,250,608 |